New hope for tough blood cancer cases: experimental drug targets relapsed disease
NCT ID NCT06986174
Summary
This study is testing whether the drug pacritinib is safe and effective for people with Waldenström macroglobulinemia, a rare blood cancer, that has come back or stopped responding to other treatments. About 30 participants who have had at least two prior treatments will receive pacritinib, which works by blocking specific proteins that help cancer cells survive and grow. The goal is to see if this drug can control the disease and reduce cancer-related symptoms.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for WALDENSTRÖM MACROGLOBULINEMIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Dana Farber Cancer Institute
RECRUITINGBoston, Massachusetts, 02115, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.